Mediantechn - Asset Resilience Ratio

Latest as of December 2025: 0.45%

Mediantechn (ALMDT) has an Asset Resilience Ratio of 0.45% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€163.00K
≈ $190.56K USD Cash + Short-term Investments

Total Assets

€35.87 Million
≈ $41.94 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2008–2025)

This chart shows how Mediantechn's Asset Resilience Ratio has changed over time. Check Mediantechn PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Mediantechn's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Mediantechn market cap and net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €163.00K 0.45%
Total Liquid Assets €163.00K 0.45%

Asset Resilience Insights

  • Limited Liquidity: Mediantechn maintains only 0.45% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Mediantechn Industry Peers by Asset Resilience Ratio

Compare Mediantechn's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shenzhen New Industries Biomedical
SHE:300832
Medical Devices 9.95%
GN Store Nord
CO:GN
Medical Devices -4.56%
Getein Biotech Inc
SHG:603387
Medical Devices 29.77%
Ningbo David Medical Device Co Ltd
SHE:300314
Medical Devices 6.89%
Vieworks Co. Ltd
KQ:100120
Medical Devices 7.81%
Somnomed Ltd
AU:SOM
Medical Devices 24.67%
Dynamic Medical Technologies
TWO:4138
Medical Devices 18.54%
T&R Biofab Co. Ltd
KQ:246710
Medical Devices 0.12%

Annual Asset Resilience Ratio for Mediantechn (2008–2025)

The table below shows the annual Asset Resilience Ratio data for Mediantechn.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.45% €163.00K
≈ $190.56K
€35.87 Million
≈ $41.94 Million
-0.17pp
2024-12-31 0.62% €151.00K
≈ $176.53K
€24.37 Million
≈ $28.49 Million
+0.28pp
2023-12-31 0.34% €123.00K
≈ $143.80K
€35.94 Million
≈ $42.01 Million
-0.23pp
2022-12-31 0.58% €200.00K
≈ $233.82K
€34.75 Million
≈ $40.63 Million
-78.90pp
2021-12-31 79.47% €39.25 Million
≈ $45.89 Million
€49.39 Million
≈ $57.74 Million
+14.62pp
2020-12-31 64.86% €16.40 Million
≈ $19.17 Million
€25.28 Million
≈ $29.56 Million
+63.98pp
2019-12-31 0.87% €141.00K
≈ $164.84K
€16.12 Million
≈ $18.85 Million
+0.36pp
2018-12-31 0.52% €94.00K
≈ $109.90K
€18.15 Million
≈ $21.22 Million
-0.09pp
2017-12-31 0.60% €206.00K
≈ $240.84K
€34.14 Million
≈ $39.92 Million
+0.34pp
2016-12-31 0.26% €123.00K
≈ $143.80K
€46.55 Million
≈ $54.43 Million
-0.01pp
2015-12-31 0.27% €91.00K
≈ $106.39K
€33.55 Million
≈ $39.22 Million
-0.05pp
2014-12-31 0.32% €58.00K
≈ $67.81K
€17.87 Million
≈ $20.89 Million
-10.31pp
2011-12-31 10.64% €1.11 Million
≈ $1.30 Million
€10.47 Million
≈ $12.24 Million
-49.54pp
2010-12-31 60.17% €2.81 Million
≈ $3.28 Million
€4.67 Million
≈ $5.46 Million
+6.27pp
2009-12-31 53.90% €2.71 Million
≈ $3.16 Million
€5.02 Million
≈ $5.87 Million
+29.99pp
2008-12-31 23.92% €1.39 Million
≈ $1.63 Million
€5.83 Million
≈ $6.81 Million
--
pp = percentage points

About Mediantechn

PA:ALMDT France Medical Devices
Market Cap
$181.54 Million
€155.28 Million EUR
Market Cap Rank
#16909 Global
#248 in France
Share Price
€4.08
Change (1 day)
-0.12%
52-Week Range
€1.89 - €6.59
All Time High
€17.80
About

Median Technologies SA engages in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development with operations spanning in France, the United States, Canada, the United Kingdom, China, and internationally. The company offers iSee for imaging services in clinical trials; eyonis for non-invasive diagnos… Read more